South Africa has put its roll-out of the Oxford-AstraZeneca vaccine on hold after a study showed 'disappointing' results against its new Covid variant. Scientists say the variant accounts for 90% of new Covid cases in South Africa. The study, involving around 2,000 people, found the vaccine offered 'minimal protection' against mild and moderate cases. But experts are hopeful that the vaccine will still be effective at preventing severe infections. South Africa has recorded more than 1.4 million cases of coronavirus and 46,000 deaths since the pandemic began, according to data collated by Johns Hopkins University. The country has received 1m doses of the Oxford-AstraZeneca jab and was due to start vaccinating people this week. Speaking at an online news conference on Sunday, South African Health Minister Zweli Mkhize said his government would wait for further advice on how best to proceed with the AstraZeneca vaccine in light of the findings. In the meantime, he said, the government will offer vaccines produced by Johnson & Johnson and Pfizer in the coming weeks. What does it mean for serious cases? The trial was carried out by researchers at the University of the Witwatersrand in South Africa and the UK's Oxford University, but has not yet been peer reviewed. The trial's chief investigator, Prof Shabir Madhi, said it showed that 'unfortunately, the AstraZeneca vaccine does not work against mild and moderate illness'. Prof Madhi said the study had not been able to investigate the vaccine's efficacy in preventing more serious infections, as participants had an average age of 31 and so did not represent the demographic most at risk of severe symptoms from the virus. The vaccine's similarity to one produced by Johnson & Johnson, which was found to reduce severe disease by 89%, suggested it would still prevent serious illness, according to Prf Madhi. 'There's still some hope that the AstraZeneca vaccine might well perform as well as the Johnson & Johnson vaccine in a different age group demographic that I address of severe disease,' he told the BBC. Other experts were also hopeful that the vaccine remained effective at combating more serious cases. 'What we're seeing from other vaccine developers is that they have a reduction in efficacy against some of the variant viruses and what that is looking like is that we may not be reducing the total number of cases, but there's still protection in that case against deaths, hospitalisations and severe disease,' Prof Sarah Gilbert, Oxford's lead vaccine developer, told the Andrew Marr Show on Sunday. She said developers were likely to have a modified version of the injection against the South Africa variant, also known as 501.V2 or B.1.351, later this year. Prof Tulio de Oliveira, an epidemiologist at the Nelson R Mandela School of Medicine, said he hoped the vaccine would still have a role to play in South Africa's inoculation programme. 'Our hope is that despite the very low efficacy on a small phase two trial in South Africa on the mild infections, that we would still see some